Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Aberrant JAK2 signalling plays a central role in myeloproliferative neoplasms (MPN). JAK2 inhibitors have proven to be clinically efficacious, however, they are not mutation-specific and competent enough to suppress neoplastic clonal haematopoiesis. We hypothesized that, by simultaneously targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartalucci, Niccolò, Tozzi, Lorenzo, Bogani, Costanza, Martinelli, Serena, Rotunno, Giada, Villeval, Jean-Luc, Vannucchi, Alessandro M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117551/
https://www.ncbi.nlm.nih.gov/pubmed/24237791
http://dx.doi.org/10.1111/jcmm.12162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117551/
https://www.ncbi.nlm.nih.gov/pubmed/24237791
http://dx.doi.org/10.1111/jcmm.12162

Ejemplares similares